載入...
Clinical potential of brodalumab in the management of psoriasis: the evidence to date
Brodalumab is an anti-IL-17 receptor monoclonal antibody currently in development for the treatment of moderate-to-severe plaque psoriasis. With many systemic psoriasis therapies to choose from, and several newer agents in development, physicians need up to date evidence for the use of these drugs....
Na minha lista:
| 發表在: | Psoriasis (Auckl) |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683110/ https://ncbi.nlm.nih.gov/pubmed/29387580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S49996 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|